196:@0.085219:0.957873:0.109687:0.957873:0.109687:0.938882:0.085219:0.938882:0.007284:0.008593:0.008591
ADDENDUM:@0.117647:0.067543:0.201421:0.067543:0.201421:0.045457:0.117647:0.045457:0.009679:0.010295:0.010295:0.008697:0.010706:0.010295:0.010226:0.013582
227. Gilmour, L. M. R. :@0.117647:0.119718:0.298165:0.119718:0.298165:0.101197:0.117647:0.101197:0.009483:0.009483:0.009483:0.004088:0.004814:0.014070:0.005229:0.004773:0.015896:0.009836:0.010376:0.005686:0.004088:0.005458:0.010563:0.004088:0.005458:0.017826:0.004088:0.005458:0.012451:0.004088:0.003735
et al.:@0.299921:0.119718:0.336817:0.119718:0.336817:0.101006:0.299921:0.101006:0.007346:0.005727:0.005582:0.009048:0.004607:0.004586
 Neuregulin expression, function, and signaling in human ovarian :@0.336822:0.119718:0.856607:0.119718:0.856607:0.101197:0.336822:0.101197:0.005458:0.014111:0.008301:0.010376:0.006765:0.008218:0.008965:0.010500:0.004773:0.005105:0.010687:0.005458:0.008280:0.009172:0.010065:0.006765:0.008218:0.006848:0.006910:0.005043:0.009857:0.010687:0.004088:0.005458:0.005790:0.010376:0.010542:0.008280:0.005852:0.005043:0.009857:0.010687:0.004088:0.005458:0.008259:0.010542:0.010355:0.005458:0.006910:0.005105:0.008965:0.010625:0.008548:0.004773:0.005105:0.010417:0.008965:0.005458:0.005105:0.010687:0.005458:0.010085:0.010376:0.015979:0.008259:0.010687:0.005458:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.003735
cancer cells. Clin. Cancer Res. 8, 3933–3942 (2002).:@0.155000:0.140297:0.549258:0.140297:0.549258:0.121776:0.155000:0.121776:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.008176:0.008135:0.004897:0.004773:0.006973:0.004088:0.003735:0.013403:0.004773:0.005105:0.010687:0.004088:0.003735:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.012451:0.008218:0.006973:0.004088:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
228. Aune, G. :@0.117647:0.160875:0.226562:0.160875:0.226562:0.142355:0.117647:0.142355:0.009483:0.009483:0.009483:0.004088:0.004814:0.012721:0.010376:0.010542:0.007948:0.004088:0.003808:0.014256:0.004088:0.003735
et al.:@0.226634:0.160875:0.261839:0.160875:0.261839:0.142164:0.226634:0.142164:0.007346:0.005727:0.003891:0.009048:0.004607:0.004586
 Increased circulating hepatocyte growth factor (HGF): A marker of epithelial :@0.261839:0.160875:0.856676:0.160875:0.856676:0.142355:0.261839:0.142355:0.003808:0.006267:0.010542:0.008176:0.006765:0.008446:0.008446:0.007159:0.008280:0.010355:0.003806:0.008176:0.005105:0.006765:0.008280:0.010500:0.004939:0.008010:0.005852:0.005105:0.010417:0.008965:0.003808:0.010272:0.008301:0.010334:0.008010:0.005644:0.010251:0.008529:0.008840:0.005644:0.008218:0.003806:0.008965:0.006765:0.009878:0.013385:0.006018:0.010417:0.003808:0.005644:0.008446:0.008280:0.005644:0.009857:0.007097:0.003808:0.006308:0.014918:0.014256:0.010334:0.006308:0.004088:0.003808:0.013572:0.003808:0.015979:0.008259:0.006910:0.009338:0.008218:0.007097:0.003808:0.009857:0.005644:0.003806:0.008301:0.010067:0.004792:0.006018:0.010272:0.008135:0.004773:0.005271:0.008550:0.004773:0.003735
ovarian cancer and an indicator of poor prognosis. Gynecologic Oncology 121, 402–406 :@0.155000:0.181454:0.856656:0.181454:0.856656:0.162933:0.155000:0.162933:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.005873:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.005873:0.008259:0.010544:0.010355:0.005873:0.008259:0.010687:0.005873:0.005105:0.010542:0.010355:0.005043:0.008280:0.008010:0.005644:0.009857:0.007097:0.005873:0.009857:0.005644:0.005873:0.010459:0.010251:0.009857:0.007097:0.005873:0.010065:0.006765:0.010044:0.008965:0.010542:0.009961:0.006910:0.005105:0.006973:0.004088:0.005873:0.014194:0.008840:0.010542:0.008280:0.008176:0.009940:0.004711:0.010044:0.008965:0.005043:0.008176:0.005873:0.014817:0.010542:0.008176:0.009940:0.004711:0.010044:0.009587:0.008840:0.005873:0.009483:0.009483:0.009483:0.004088:0.005873:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735
(2011).:@0.155000:0.202033:0.209639:0.202033:0.209639:0.183512:0.155000:0.183512:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
229. Sheng, Q. :@0.117647:0.222612:0.230681:0.222612:0.230681:0.204091:0.117647:0.204091:0.009483:0.009483:0.009483:0.004088:0.004814:0.008923:0.010272:0.008218:0.010417:0.008799:0.004088:0.003217:0.013924:0.004088:0.003735
et al.:@0.230170:0.222612:0.264784:0.222612:0.264784:0.203900:0.230170:0.203900:0.007346:0.005727:0.003300:0.009048:0.004607:0.004586
 An Activated ErbB3/NRG1 Autocrine Loop Supports :@0.264775:0.222612:0.679868:0.222612:0.679868:0.204091:0.264775:0.204091:0.003217:0.013572:0.010687:0.003217:0.013032:0.008280:0.005852:0.005043:0.008944:0.008010:0.005642:0.008280:0.010355:0.003217:0.010998:0.007014:0.010023:0.011496:0.009483:0.006454:0.014754:0.012098:0.014256:0.009483:0.003217:0.012721:0.010065:0.005644:0.010251:0.008176:0.007097:0.005105:0.010542:0.008218:0.003217:0.010749:0.010251:0.009836:0.010251:0.003217:0.008902:0.010065:0.010044:0.010459:0.009857:0.007242:0.005852:0.006973:0.003735
In Vivo:@0.679375:0.222612:0.732978:0.222612:0.732978:0.203900:0.679375:0.203900:0.005582:0.010272:0.003300:0.012430:0.004692:0.008301:0.009027
 Proliferation in :@0.732969:0.222612:0.856669:0.222612:0.856669:0.204091:0.732969:0.204091:0.003217:0.010832:0.006765:0.009940:0.004773:0.005105:0.005478:0.008218:0.007180:0.008010:0.005852:0.005043:0.009857:0.010687:0.003217:0.005105:0.010687:0.003735
Ovarian Cancer Cells. Cancer Cell 17, 298–310 (2010).:@0.155000:0.243190:0.576090:0.243190:0.576090:0.224669:0.155000:0.224669:0.015356:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.003735:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.013632:0.008135:0.004897:0.004773:0.006973:0.004088:0.003735:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.013634:0.008135:0.004897:0.004773:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
230. Bourgeois, D. L., Kabarowski, K. A., Porubsky, V. L. & Kreeger, P. K. High-grade serous ovar-:@0.117647:0.263769:0.852941:0.263769:0.852941:0.245248:0.117647:0.245248:0.009483:0.009483:0.009483:0.004088:0.004814:0.011891:0.009836:0.010376:0.006931:0.008778:0.008280:0.009857:0.005105:0.006973:0.004088:0.003632:0.013738:0.004088:0.003632:0.010563:0.004088:0.004088:0.003632:0.012866:0.008280:0.010106:0.008259:0.006765:0.009878:0.013385:0.006869:0.009733:0.004856:0.004088:0.003632:0.013219:0.004088:0.003632:0.013572:0.004088:0.004088:0.003632:0.010148:0.009857:0.007242:0.010314:0.009940:0.006869:0.009504:0.007263:0.004088:0.003632:0.010438:0.004088:0.003632:0.010563:0.004088:0.003632:0.014298:0.003632:0.013157:0.006765:0.008280:0.008218:0.008778:0.008218:0.005686:0.004088:0.003632:0.008010:0.004088:0.003632:0.013219:0.004088:0.003632:0.014983:0.005105:0.009027:0.010417:0.006848:0.008965:0.007178:0.008446:0.010293:0.008218:0.003632:0.007159:0.008218:0.006765:0.009836:0.010376:0.006973:0.003632:0.009876:0.008944:0.008261:0.006624:0.006848
ian cancer cell lines exhibit heterogeneous responses to growth factor stimulation. Cancer :@0.155000:0.284348:0.856631:0.284348:0.856631:0.265827:0.155000:0.265827:0.005271:0.008259:0.010687:0.005126:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.005126:0.008176:0.008135:0.004897:0.004773:0.005126:0.004773:0.005105:0.010542:0.008218:0.006973:0.005126:0.008280:0.009172:0.010417:0.005041:0.009836:0.004794:0.005852:0.005126:0.010272:0.008301:0.005644:0.008218:0.006765:0.010044:0.008778:0.008218:0.010542:0.008280:0.009836:0.010376:0.006973:0.005126:0.006765:0.008218:0.006829:0.010457:0.009857:0.010563:0.007159:0.008218:0.006973:0.005126:0.005644:0.010044:0.005126:0.008965:0.006765:0.009878:0.013385:0.006018:0.010417:0.005126:0.005644:0.008446:0.008280:0.005644:0.009857:0.007097:0.005126:0.006827:0.005852:0.005105:0.015709:0.010500:0.004939:0.008010:0.005852:0.005043:0.009857:0.010687:0.004088:0.005126:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735
Cell Int. 15, 112 (2015).:@0.155000:0.304926:0.334086:0.304926:0.334086:0.286406:0.155000:0.286406:0.013634:0.008135:0.004897:0.004773:0.003735:0.006267:0.010355:0.005852:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
231. Antoniou, A. :@0.117647:0.325505:0.261508:0.325505:0.261508:0.306984:0.117647:0.306984:0.009483:0.009483:0.009483:0.004088:0.004814:0.013572:0.010355:0.005644:0.009857:0.010687:0.005043:0.009836:0.010127:0.004088:0.005904:0.013572:0.004088:0.003735
et al.:@0.263676:0.325505:0.301029:0.325505:0.301029:0.306793:0.263676:0.306793:0.007346:0.005727:0.006039:0.009048:0.004607:0.004586
 Average risks of breast and ovarian cancer associated with BRCA1 or :@0.301024:0.325505:0.856678:0.325505:0.856678:0.306984:0.301024:0.306984:0.005904:0.012223:0.008757:0.008218:0.007180:0.008363:0.008778:0.008218:0.005904:0.007097:0.005105:0.006869:0.009566:0.006973:0.005904:0.009857:0.005644:0.005904:0.009836:0.006765:0.008446:0.008446:0.006827:0.005852:0.005904:0.008259:0.010542:0.010355:0.005904:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.005904:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.005904:0.008446:0.006848:0.007159:0.010251:0.008176:0.005269:0.008010:0.005644:0.008280:0.010355:0.005904:0.013385:0.004794:0.006018:0.010417:0.005904:0.011330:0.012098:0.013343:0.013572:0.009483:0.005904:0.009857:0.007097:0.003735
BRCA2 mutations detected in case Series unselected for family history: a combined analysis :@0.155000:0.346084:0.856718:0.346084:0.856718:0.327563:0.155000:0.327563:0.011330:0.012098:0.013343:0.013572:0.009483:0.003652:0.015709:0.010065:0.005956:0.008010:0.005852:0.005043:0.009857:0.010563:0.006973:0.003652:0.010293:0.008301:0.005644:0.008280:0.008280:0.005644:0.008280:0.010355:0.003652:0.005105:0.010687:0.003652:0.008280:0.008446:0.007159:0.008218:0.003652:0.009629:0.008218:0.007097:0.005043:0.008218:0.006973:0.003652:0.010376:0.010563:0.007159:0.008135:0.004711:0.008280:0.008280:0.005644:0.008280:0.010355:0.003652:0.005478:0.009857:0.007097:0.003652:0.005644:0.008259:0.016041:0.005227:0.004713:0.008840:0.003652:0.010417:0.005105:0.006827:0.005644:0.009857:0.007637:0.009255:0.004088:0.003652:0.008446:0.003652:0.008176:0.009857:0.015813:0.009836:0.005105:0.010542:0.008280:0.010355:0.003652:0.008259:0.010627:0.008550:0.004709:0.008840:0.006912:0.005105:0.006973:0.003735
of 22 studies. Am. J. Hum. Genet. 72, 1117–1130 (2003).:@0.155000:0.366663:0.583975:0.366663:0.583975:0.348142:0.155000:0.348142:0.009857:0.005644:0.003735:0.009483:0.009483:0.003735:0.006827:0.005603:0.010314:0.010355:0.005043:0.008218:0.006973:0.004088:0.003735:0.013572:0.016041:0.004088:0.003735:0.005103:0.004088:0.003735:0.014402:0.010376:0.016041:0.004088:0.003735:0.014381:0.008218:0.010542:0.008301:0.005852:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
232. Gabai-Kapara, E. :@0.117647:0.387241:0.291419:0.387241:0.291419:0.368720:0.117647:0.368720:0.009483:0.009483:0.009483:0.004088:0.004814:0.014360:0.008280:0.010106:0.008259:0.005105:0.006848:0.012864:0.008010:0.010334:0.008259:0.007180:0.008446:0.004088:0.005458:0.010998:0.004088:0.003735
et al.:@0.293137:0.387241:0.330033:0.387241:0.330033:0.368529:0.293137:0.368529:0.007346:0.005727:0.005582:0.009048:0.004607:0.004586
 Population-based screening for breast and ovarian cancer risk due :@0.330026:0.387241:0.856700:0.387241:0.856700:0.368720:0.330026:0.368720:0.005458:0.010148:0.009836:0.010044:0.010500:0.004939:0.008010:0.005852:0.005043:0.009857:0.010687:0.006848:0.010104:0.008446:0.007159:0.008280:0.010355:0.005458:0.007159:0.008176:0.006765:0.008280:0.008218:0.010687:0.005105:0.010415:0.008965:0.005458:0.005478:0.009857:0.007097:0.005458:0.009836:0.006765:0.008446:0.008446:0.006827:0.005852:0.005458:0.008259:0.010542:0.010355:0.005458:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.005458:0.008280:0.008259:0.010544:0.008176:0.008218:0.007097:0.005458:0.007097:0.005105:0.006869:0.009566:0.005458:0.010044:0.010314:0.008218:0.003735
toBRCA1andBRCA2. Proceedings of the National Academy of Sciences 111, 14205–14210 :@0.155000:0.407820:0.856612:0.407820:0.856612:0.389299:0.155000:0.389299:0.005644:0.010044:0.011330:0.012098:0.013343:0.013572:0.009483:0.008259:0.010542:0.010355:0.011330:0.012098:0.013343:0.013572:0.009483:0.004088:0.004088:0.010832:0.006765:0.010251:0.008176:0.008280:0.008280:0.010355:0.005105:0.010417:0.008840:0.006973:0.004088:0.009857:0.005644:0.004088:0.006018:0.010272:0.008218:0.004088:0.014132:0.008010:0.005852:0.005043:0.009857:0.010625:0.008550:0.004773:0.004088:0.013032:0.008280:0.008446:0.010293:0.008218:0.015688:0.008840:0.004088:0.009857:0.005644:0.004088:0.009629:0.008176:0.005043:0.008218:0.010542:0.008176:0.008218:0.006973:0.004088:0.009483:0.009483:0.009483:0.004088:0.004088:0.009483:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.009483:0.003735
(2014).:@0.155000:0.428399:0.209639:0.428399:0.209639:0.409878:0.155000:0.409878:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
233. Wang, M. :@0.117647:0.448977:0.233669:0.448977:0.233669:0.430456:0.117647:0.430456:0.009483:0.009483:0.009483:0.004088:0.004814:0.017079:0.008259:0.010417:0.008799:0.004088:0.004379:0.017826:0.004088:0.003735
et al.:@0.234324:0.448977:0.270121:0.448977:0.270121:0.430265:0.234324:0.430265:0.007346:0.005727:0.004482:0.009048:0.004607:0.004586
 PAX2 and PAX8 Reliably Distinguishes Ovarian Serous Tumors From Mu-:@0.270119:0.448977:0.852941:0.448977:0.852941:0.430456:0.270119:0.430456:0.004379:0.009315:0.013655:0.012825:0.009483:0.004379:0.008259:0.010542:0.010355:0.004379:0.009317:0.013655:0.012825:0.009483:0.004379:0.012451:0.008135:0.004773:0.005271:0.008280:0.009919:0.004711:0.008840:0.004379:0.014568:0.005105:0.006827:0.005852:0.005105:0.010417:0.008965:0.010376:0.005105:0.006869:0.010272:0.008218:0.006973:0.004379:0.015356:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.004379:0.009627:0.008218:0.006765:0.009836:0.010376:0.006973:0.004379:0.009919:0.010376:0.015896:0.009857:0.006931:0.006973:0.004379:0.009774:0.006765:0.009857:0.016041:0.004379:0.016956:0.010432:0.006848
cinous  Tumors. Applied Immunohistochemistry  &  Molecular  Morphology 23,  280–287 :@0.155000:0.469556:0.856704:0.469556:0.856704:0.451035:0.155000:0.451035:0.008176:0.005105:0.010542:0.009836:0.010376:0.006973:0.003735:0.003206:0.009919:0.010376:0.015896:0.009857:0.006931:0.006973:0.004088:0.006952:0.012721:0.010044:0.010148:0.004773:0.005043:0.008278:0.010355:0.006952:0.006267:0.016041:0.015709:0.010376:0.010542:0.009940:0.010417:0.005105:0.006827:0.005644:0.010251:0.007969:0.010272:0.008218:0.016041:0.005105:0.006827:0.005852:0.007637:0.008840:0.003735:0.003206:0.014298:0.003735:0.003206:0.017245:0.009940:0.004711:0.008280:0.008280:0.010500:0.004939:0.008259:0.007097:0.003735:0.003206:0.017245:0.009859:0.007240:0.010148:0.010272:0.009940:0.004711:0.010044:0.009587:0.008840:0.006952:0.009483:0.009483:0.004088:0.003735:0.003206:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735
(2015).:@0.155000:0.490135:0.209639:0.490135:0.209639:0.471614:0.155000:0.471614:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
234. Rajagopalan, H. & Lengauer, C. Aneuploidy and cancer. Nature 432, 338–341 (2004).:@0.117647:0.510713:0.802841:0.510713:0.802841:0.492193:0.117647:0.492193:0.009483:0.009483:0.009483:0.004088:0.004814:0.012638:0.008010:0.004794:0.008363:0.008778:0.009836:0.010334:0.008550:0.004939:0.008259:0.010687:0.004088:0.003735:0.015315:0.004088:0.003735:0.014298:0.003735:0.010747:0.008218:0.010417:0.008965:0.008010:0.010314:0.008218:0.005686:0.004088:0.003735:0.013343:0.004088:0.003735:0.013572:0.010542:0.008299:0.010065:0.010150:0.004711:0.009857:0.005043:0.010293:0.008840:0.003735:0.008257:0.010544:0.010355:0.003735:0.008278:0.008261:0.010542:0.008176:0.008218:0.005686:0.004088:0.003735:0.014130:0.008010:0.005603:0.010376:0.006765:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
235. Gorringe, K. L. :@0.117647:0.531292:0.275940:0.531292:0.275940:0.512771:0.117647:0.512771:0.009483:0.009483:0.009483:0.004088:0.004814:0.014381:0.009857:0.007097:0.007097:0.005105:0.010417:0.008778:0.007948:0.004088:0.005240:0.013219:0.004088:0.005240:0.010563:0.004088:0.003735
et al.:@0.277445:0.531292:0.314113:0.531292:0.314113:0.512580:0.277445:0.512580:0.007346:0.005727:0.005354:0.009048:0.004607:0.004586
 High-Resolution Single Nucleotide Polymorphism Array Analysis of :@0.314115:0.531292:0.856687:0.531292:0.856687:0.512771:0.314115:0.512771:0.005240:0.014983:0.005105:0.009027:0.010417:0.006848:0.012451:0.008218:0.007159:0.009940:0.004462:0.010065:0.005852:0.005043:0.009859:0.010687:0.005240:0.009193:0.005105:0.010417:0.009025:0.004711:0.008218:0.005250:0.014007:0.010314:0.007969:0.004711:0.008280:0.009836:0.005852:0.005043:0.010293:0.008218:0.005240:0.010148:0.009940:0.004711:0.008840:0.015896:0.009857:0.007242:0.010148:0.010417:0.005105:0.006910:0.016041:0.005240:0.013572:0.007097:0.007180:0.008114:0.008840:0.005240:0.013572:0.010625:0.008550:0.004711:0.008840:0.006910:0.005105:0.006973:0.005240:0.009857:0.005644:0.003735
Epithelial Ovarian Cancer Reveals Numerous Microdeletions and Amplifications. Clinical :@0.155000:0.551871:0.856656:0.551871:0.856656:0.533350:0.155000:0.533350:0.010459:0.010065:0.004794:0.006018:0.010272:0.008135:0.004773:0.005271:0.008550:0.004773:0.004814:0.015356:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.004814:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.004814:0.012451:0.008487:0.008757:0.008446:0.008550:0.004773:0.006973:0.004814:0.014007:0.010376:0.015896:0.008218:0.006765:0.009836:0.010376:0.006973:0.004814:0.017660:0.005043:0.008176:0.006765:0.010251:0.010293:0.008135:0.004711:0.008301:0.005852:0.005043:0.009857:0.010563:0.006973:0.004814:0.008261:0.010542:0.010355:0.004814:0.013572:0.015709:0.010148:0.004773:0.005105:0.005167:0.005105:0.008280:0.008010:0.005852:0.005043:0.009857:0.010563:0.006973:0.004088:0.004814:0.013406:0.004773:0.005105:0.010687:0.005043:0.008280:0.008550:0.004773:0.003735
Cancer Research 13, 4731–4739 (2007).:@0.155000:0.572450:0.459820:0.572450:0.459820:0.553929:0.155000:0.553929:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.012451:0.008218:0.007157:0.008446:0.008259:0.006765:0.007971:0.010417:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
236. Hunter, S. M. :@0.117647:0.593028:0.259422:0.593028:0.259422:0.574507:0.117647:0.574507:0.009483:0.009483:0.009483:0.004088:0.004814:0.014402:0.010376:0.010355:0.005644:0.008218:0.005686:0.004088:0.003362:0.009193:0.004088:0.003362:0.017826:0.004088:0.003735
et al.:@0.259036:0.593028:0.293774:0.593028:0.293774:0.574316:0.259036:0.574316:0.007346:0.005727:0.003424:0.009048:0.004607:0.004586
 Pre-Invasive Ovarian Mucinous Tumors Are Characterized by CDKN2A :@0.293782:0.593028:0.856711:0.593028:0.856711:0.574507:0.293782:0.574507:0.003362:0.010832:0.006765:0.008218:0.006848:0.006267:0.010334:0.008944:0.008446:0.006910:0.005043:0.008757:0.008218:0.003362:0.015356:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.003362:0.016954:0.010314:0.008176:0.005105:0.010542:0.009836:0.010376:0.006973:0.003362:0.009919:0.010376:0.015898:0.009855:0.006933:0.006973:0.003362:0.013572:0.006765:0.008218:0.003362:0.013406:0.010355:0.008259:0.007180:0.008446:0.008278:0.005647:0.008218:0.007097:0.005105:0.008031:0.008278:0.010355:0.003362:0.009857:0.008840:0.003362:0.013343:0.014339:0.013219:0.014754:0.009483:0.013572:0.003735
and RAS Pathway Aberrations. Clinical Cancer Research 18, 5267–5277 (2012).:@0.155000:0.613607:0.764388:0.613607:0.764388:0.595086:0.155000:0.595086:0.008259:0.010542:0.010355:0.003735:0.012409:0.013696:0.009193:0.003735:0.010376:0.008010:0.006018:0.010065:0.013385:0.008114:0.008840:0.003735:0.012905:0.010231:0.008218:0.007097:0.007180:0.008010:0.005852:0.005043:0.009857:0.010563:0.006973:0.004088:0.003735:0.013406:0.004773:0.005105:0.010687:0.005043:0.008278:0.008550:0.004773:0.003735:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.012451:0.008218:0.007159:0.008444:0.008261:0.006765:0.007969:0.010417:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
237. Romero, I., Sun, C. C., Wong, K. K., Bast, R. C. & Gershenson, D. M. Low-grade serous carci-:@0.117647:0.634186:0.852941:0.634186:0.852941:0.615665:0.117647:0.615665:0.009483:0.009483:0.009483:0.004088:0.004814:0.012451:0.009857:0.015896:0.008218:0.006765:0.009338:0.004088:0.003279:0.006599:0.004088:0.004088:0.003279:0.008902:0.010376:0.010687:0.004088:0.003279:0.013343:0.004088:0.003279:0.013343:0.004088:0.004088:0.003279:0.016954:0.009857:0.010417:0.008799:0.004088:0.003279:0.013219:0.004088:0.003279:0.013219:0.004088:0.004088:0.003279:0.011702:0.008446:0.006829:0.005852:0.004088:0.003279:0.012451:0.004088:0.003279:0.013343:0.004088:0.003279:0.014298:0.003279:0.014381:0.008218:0.006931:0.006869:0.010272:0.008218:0.010563:0.007159:0.009857:0.010687:0.004088:0.003279:0.013738:0.004088:0.003279:0.017826:0.004088:0.003279:0.010749:0.009878:0.013385:0.006848:0.008965:0.007178:0.008446:0.010293:0.008218:0.003279:0.007157:0.008218:0.006765:0.009836:0.010376:0.006973:0.003279:0.008280:0.008261:0.006765:0.008176:0.005213:0.006848
noma: New concepts and emerging therapies. Gynecologic Oncology 130, 660–666 (2013).:@0.155000:0.654764:0.849492:0.654764:0.849492:0.636244:0.155000:0.636244:0.010542:0.009857:0.015979:0.008446:0.004088:0.003735:0.014111:0.008487:0.013385:0.003735:0.008176:0.009857:0.010542:0.008176:0.008301:0.010044:0.005852:0.006973:0.003735:0.008259:0.010542:0.010355:0.003735:0.008218:0.015896:0.008218:0.006931:0.008965:0.005105:0.010417:0.008965:0.003735:0.006016:0.010274:0.008218:0.007178:0.008010:0.010065:0.005043:0.008218:0.006973:0.004088:0.003735:0.014194:0.008840:0.010542:0.008280:0.008176:0.009940:0.004711:0.010044:0.008965:0.005043:0.008176:0.003735:0.014817:0.010542:0.008176:0.009940:0.004711:0.010044:0.009587:0.008840:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
238. Kuo, K.-T. :@0.117647:0.675343:0.236118:0.675343:0.236118:0.656822:0.117647:0.656822:0.009483:0.009483:0.009483:0.004088:0.004814:0.012409:0.010314:0.009338:0.004088:0.003030:0.013219:0.004088:0.006848:0.009961:0.004088:0.003735
et al.:@0.235409:0.675343:0.269815:0.675343:0.269815:0.656631:0.235409:0.656631:0.007346:0.005727:0.003092:0.009048:0.004607:0.004586
 Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Iden-:@0.269818:0.675343:0.852941:0.675343:0.852941:0.656822:0.269818:0.656822:0.003030:0.013572:0.010625:0.008550:0.004711:0.008840:0.006910:0.005105:0.006973:0.003030:0.009857:0.005644:0.003030:0.014339:0.014007:0.013572:0.003030:0.013634:0.009836:0.010085:0.008840:0.003030:0.014007:0.010376:0.015813:0.010231:0.008218:0.007097:0.003030:0.013696:0.004462:0.005644:0.008218:0.007180:0.008010:0.005852:0.005043:0.009857:0.010563:0.006973:0.003030:0.005105:0.010687:0.003030:0.015356:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.003030:0.009629:0.008218:0.006765:0.009836:0.010376:0.006973:0.003030:0.009919:0.010376:0.015896:0.009857:0.006931:0.006973:0.003030:0.006018:0.010293:0.008218:0.010669:0.006848
tifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas. Cancer :@0.155000:0.695922:0.856758:0.695922:0.856758:0.677401:0.155000:0.677401:0.005852:0.005105:0.005167:0.005105:0.008218:0.006973:0.003715:0.014111:0.008487:0.013385:0.003715:0.017245:0.009940:0.004711:0.008280:0.008280:0.010500:0.004939:0.008259:0.007097:0.003715:0.014381:0.008218:0.010542:0.008301:0.005852:0.005043:0.008176:0.003715:0.013403:0.010355:0.008259:0.010419:0.008778:0.008218:0.006973:0.003715:0.005105:0.010687:0.003715:0.010749:0.009878:0.013385:0.006848:0.014070:0.007180:0.008446:0.010293:0.008218:0.003715:0.008259:0.010542:0.010355:0.003715:0.014983:0.005105:0.009027:0.010417:0.006848:0.014070:0.007180:0.008446:0.010293:0.008218:0.003715:0.013613:0.008259:0.006765:0.008176:0.005105:0.010542:0.009857:0.015979:0.008446:0.006973:0.004088:0.003715:0.013611:0.008259:0.010544:0.008176:0.008218:0.007097:0.003735
Research 69, 4036–4042 (2009).:@0.155000:0.716500:0.400180:0.716500:0.400180:0.697980:0.155000:0.697980:0.012451:0.008218:0.007159:0.008446:0.008259:0.006765:0.007969:0.010417:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
239. Seidman, J. D., Yemelyanova, A., Zaino, R. J. & Kurman, R. J. The Fallopian Tube-Peritoneal :@0.117647:0.737079:0.856675:0.737079:0.856675:0.718558:0.117647:0.718558:0.009483:0.009483:0.009483:0.004088:0.004814:0.009629:0.008218:0.005043:0.010355:0.015979:0.008259:0.010687:0.004088:0.004181:0.005105:0.004088:0.004181:0.013738:0.004088:0.004088:0.004181:0.009525:0.008218:0.015896:0.008135:0.004711:0.008840:0.008259:0.010542:0.009878:0.008944:0.008446:0.004088:0.004181:0.013572:0.004088:0.004088:0.004181:0.012264:0.008259:0.005105:0.010542:0.009338:0.004088:0.004181:0.012451:0.004088:0.004181:0.005105:0.004088:0.004181:0.014298:0.004181:0.012412:0.010376:0.007097:0.015977:0.008261:0.010687:0.004088:0.004181:0.012451:0.004088:0.004181:0.005105:0.004088:0.004181:0.010428:0.010282:0.008218:0.004181:0.009753:0.008550:0.004897:0.004711:0.009836:0.010065:0.005271:0.008259:0.010687:0.004181:0.009919:0.010314:0.010231:0.008218:0.006848:0.010148:0.008218:0.007097:0.004794:0.005644:0.009857:0.010542:0.008446:0.008548:0.004773:0.003735
Junction. International Journal of Gynecological Pathology 30, 4–11 (2011).:@0.155000:0.757658:0.733512:0.757658:0.733512:0.739137:0.155000:0.739137:0.005561:0.010376:0.010542:0.008280:0.005852:0.005043:0.009857:0.010687:0.004088:0.003735:0.006267:0.010355:0.005644:0.008218:0.007097:0.010625:0.008010:0.005852:0.005043:0.009857:0.010625:0.008550:0.004773:0.003735:0.005665:0.009836:0.010376:0.007097:0.010625:0.008550:0.004773:0.003735:0.009857:0.005644:0.003735:0.014194:0.008840:0.010542:0.008278:0.008176:0.009940:0.004711:0.010044:0.008965:0.005043:0.008280:0.008550:0.004773:0.003735:0.010376:0.008010:0.006018:0.010272:0.009940:0.004711:0.010044:0.009587:0.008840:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.010729:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
240. Kurman, R. J. & Shih, I.-M. Molecular pathogenesis and extraovarian origin of epithelial :@0.117647:0.778237:0.856677:0.778237:0.856677:0.759716:0.117647:0.759716:0.009483:0.009483:0.009483:0.004088:0.004814:0.012409:0.010376:0.007097:0.015979:0.008259:0.010687:0.004088:0.006006:0.012451:0.004088:0.006008:0.005105:0.004088:0.006006:0.014298:0.006006:0.008925:0.010417:0.005227:0.010417:0.004088:0.006008:0.006599:0.004088:0.006848:0.017826:0.004088:0.006006:0.017245:0.009940:0.004711:0.008280:0.008278:0.010502:0.004937:0.008259:0.007097:0.006008:0.010334:0.008010:0.006018:0.010272:0.010044:0.008778:0.008218:0.010542:0.008218:0.006910:0.005105:0.006973:0.006006:0.008259:0.010542:0.010355:0.006008:0.008280:0.009172:0.005852:0.007178:0.008446:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.006008:0.009857:0.007097:0.005105:0.008965:0.005105:0.010687:0.006006:0.009857:0.005644:0.006006:0.008301:0.010065:0.004794:0.006018:0.010272:0.008135:0.004773:0.005271:0.008550:0.004773:0.003735
ovarian cancer—Shifting the paradigm. Human Pathology 42, 918–931 (2011).:@0.155000:0.798815:0.756214:0.798815:0.756214:0.780294:0.155000:0.780294:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.003735:0.008280:0.008259:0.010542:0.008176:0.008218:0.006578:0.016581:0.008923:0.010417:0.005105:0.005634:0.005634:0.005105:0.010417:0.008965:0.003735:0.006018:0.010272:0.008218:0.003735:0.010332:0.008259:0.007180:0.008446:0.010355:0.005105:0.008965:0.016041:0.004088:0.003735:0.014402:0.010376:0.015979:0.008259:0.010687:0.003735:0.010376:0.008010:0.006018:0.010272:0.009940:0.004711:0.010044:0.009587:0.008840:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
241. Seidman, J. D. & Khedmati, F. Exploring the histogenesis of ovarian mucinous and transi-:@0.117647:0.819394:0.852941:0.819394:0.852941:0.800873:0.117647:0.800873:0.009483:0.009483:0.009483:0.004088:0.004814:0.009629:0.008218:0.005043:0.010355:0.015979:0.008259:0.010687:0.004088:0.005126:0.005105:0.004088:0.005126:0.013738:0.004088:0.005126:0.014298:0.005126:0.013364:0.010272:0.008280:0.010355:0.015979:0.008010:0.005852:0.004856:0.004088:0.005126:0.007906:0.004088:0.005126:0.011061:0.009172:0.010145:0.004713:0.009855:0.007097:0.005105:0.010417:0.008965:0.005126:0.006018:0.010272:0.008218:0.005126:0.010417:0.005105:0.006827:0.005644:0.010044:0.008778:0.008218:0.010542:0.008218:0.006910:0.005105:0.006973:0.005126:0.009857:0.005644:0.005126:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.005126:0.015709:0.010314:0.008176:0.005105:0.010542:0.009836:0.010376:0.006973:0.005126:0.008259:0.010542:0.010355:0.005126:0.005852:0.007180:0.008259:0.010563:0.006910:0.005171:0.006848
tional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 :@0.155000:0.839973:0.856755:0.839973:0.856755:0.821452:0.155000:0.821452:0.005852:0.005043:0.009857:0.010625:0.008550:0.004773:0.003092:0.008176:0.008135:0.004897:0.004773:0.003092:0.006308:0.011349:0.006765:0.008218:0.010687:0.010542:0.008218:0.007097:0.006308:0.003092:0.010542:0.008280:0.009836:0.010145:0.004939:0.008446:0.006910:0.015919:0.006973:0.003092:0.008259:0.010542:0.010355:0.003092:0.006018:0.010272:0.008218:0.005105:0.007097:0.003092:0.006765:0.008135:0.004937:0.008012:0.005852:0.005041:0.009859:0.010563:0.006869:0.010417:0.004794:0.010251:0.003092:0.013385:0.004792:0.006018:0.010417:0.003092:0.017079:0.008550:0.004462:0.006018:0.010355:0.008259:0.006765:0.010355:0.003092:0.008176:0.008135:0.004897:0.004773:0.003092:0.010542:0.008218:0.006829:0.005852:0.006973:0.004088:0.003092:0.008446:0.003092:0.006827:0.005603:0.010314:0.010293:0.008840:0.003092:0.009857:0.005644:0.003092:0.009483:0.009483:0.009483:0.003735
tumors. Arch. Pathol. Lab. Med. 132, 1753–1760 (2008).:@0.155000:0.860551:0.582979:0.860551:0.582979:0.842031:0.155000:0.842031:0.005603:0.010376:0.015896:0.009857:0.006931:0.006973:0.004088:0.003735:0.013572:0.006765:0.007969:0.010417:0.004088:0.003735:0.010376:0.008010:0.006018:0.010272:0.009940:0.004524:0.004088:0.003735:0.010895:0.008280:0.009317:0.004088:0.003735:0.017243:0.008280:0.010106:0.004088:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
242. Vassilev, L. T. :@0.117647:0.881130:0.265336:0.881130:0.265336:0.862609:0.117647:0.862609:0.009483:0.009483:0.009483:0.004088:0.004814:0.011704:0.008446:0.006848:0.006910:0.005229:0.004711:0.008487:0.007367:0.004088:0.007056:0.010563:0.004088:0.007056:0.009961:0.004088:0.003735
In  Vivo:@0.268654:0.881130:0.326170:0.881130:0.326170:0.862418:0.268654:0.862418:0.005582:0.010272:0.003818:0.003393:0.012430:0.004690:0.008303:0.009027
 Activation of the p53 Pathway by Small-Molecule Antagonists of :@0.326168:0.881130:0.856683:0.881130:0.856683:0.862609:0.326168:0.862609:0.007056:0.013032:0.008280:0.005852:0.005043:0.008944:0.008010:0.005852:0.005043:0.009857:0.010687:0.007056:0.009857:0.005644:0.007056:0.006018:0.010272:0.008218:0.007056:0.010251:0.009483:0.009483:0.007056:0.010376:0.008010:0.006018:0.010065:0.013385:0.008114:0.008840:0.007056:0.009857:0.008840:0.007056:0.009193:0.015979:0.008550:0.004897:0.004773:0.006848:0.017245:0.009940:0.004711:0.008280:0.008280:0.010500:0.004711:0.008218:0.007056:0.013572:0.010355:0.005954:0.008363:0.008780:0.009857:0.010687:0.005105:0.006827:0.005852:0.006973:0.007056:0.009857:0.005644:0.003735
MDM2. Science 303, 844–848 (2004).:@0.155000:0.901709:0.446060:0.901709:0.446060:0.883188:0.155000:0.883188:0.017826:0.014090:0.017826:0.009483:0.004088:0.003735:0.009627:0.008176:0.005043:0.008218:0.010542:0.008176:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088